Therapeutics for Brain Metastases, v3

Patricia S Steeg; Alexandra Zimmer; Brunilde Gril

doi:10.1158/1078-0432.CCR-16-2035

Therapeutics for Brain Metastases, v3

Clin Cancer Res. 2016 Dec 15;22(24):5953-5955. doi: 10.1158/1078-0432.CCR-16-2035. Epub 2016 Oct 10.

Authors

Patricia S Steeg¹, Alexandra Zimmer², Brunilde Gril²

Affiliations

¹ Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. steegp@mail.nih.gov.
² Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.

Abstract

The role of blood-brain barrier (BBB) permeability in the efficacy of brain metastasis therapeutics is debated. Both BBB-permeable and BBB-impermeable compounds were compared in a melanoma brain metastasis model using imaging through a cranial window. Only the BBB-permeable compound inhibited both the ∼30% permeable metastases and the ∼70% impermeable metastases. Clin Cancer Res; 22(24); 5953-5. ©2016 AACRSee related article by Osswald et al., p. 6078.

MeSH terms

Animals
Antineoplastic Agents / pharmacology*
Antineoplastic Agents / therapeutic use*
Blood-Brain Barrier / metabolism
Brain / drug effects
Brain Neoplasms / drug therapy*
Brain Neoplasms / metabolism
Brain Neoplasms / secondary
Humans
Permeability

Substances

Antineoplastic Agents

Grants and funding

Z01 BC010538-05/Intramural NIH HHS/United States